Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02283268 · ClinicalTrials.gov registry record · Phase 3
Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery
A Phase 3 study of Von Willebrand Disease, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
- 20
- Study locations
NCT02283268 is a Phase 3 study of Von Willebrand Disease that has completed, run by Baxalta now part of Shire. The registered enrollment target is 24 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT02283268, a Phase 3 study of Von Willebrand Disease, has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to assess the efficacy and safety of recombinant von Willebrand factor (rVWF) with or without ADVATE in major and minor elective surgical procedures in adult patients with hereditary severe von Willebrand disease (VWD).
Conditions Studied
Interventions
- BIOLOGICAL Recombinant von Willebrand Factor (rVWF)
Study Locations (20)
Other
- AKH - Medizinische Universität Wien - Vienna
- Fakultni nemocnice Ostrava - Ostrava
- Azienda Ospedaliero - Universitaria Careggi - Firenze (Florence)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Milan
Ohio
- Case Western Reserve University Hospital - Cleveland
- Cleveland Clinic - Cleveland
Western Australia
- The Perth Blood Institute - Nedlands
- Fiona Stanley Hospital - Perth
Colorado
- University of Colorado Hemophilia & Thrombosis Center - Aurora
Florida
- University of Miami, Jackson Memorial Hospital - Miami
Georgia
- Georgia Regents University - Augusta
Maryland
- John Hopkins University - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-04-01 |
| Est. Completion | 2016-07-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02283268
The ClinicalTrials.gov registry entry for NCT02283268 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxalta now part of Shire, which has 74 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Von Willebrand Disease appearing as the primary indexed condition, and to 1 intervention - of which Recombinant von Willebrand Factor (rVWF) is the first listed.
NCT02283268 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, Ohio, Western Australia.
Frequently Asked Questions
What is clinical trial NCT02283268 about?
NCT02283268 is a clinical study titled "Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery". The purpose of the study is to assess the efficacy and safety of recombinant von Willebrand factor (rVWF) with or without ADVATE in major and minor elective surgical procedures in adult patients with hereditary severe von Willebrand disease (VWD).
What is the current status of trial NCT02283268?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2015-04-01. Estimated completion is 2016-07-06.
What conditions does trial NCT02283268 study?
This clinical trial studies the following conditions: Von Willebrand Disease.
What interventions are being tested in trial NCT02283268?
The interventions under investigation include: Recombinant von Willebrand Factor (rVWF) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02283268?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02283268 being conducted?
This trial has 20 study locations across Colorado, Florida, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Von Willebrand Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.